Semagacestat

Semagacestat is an experimental drug developed to treat Alzheimer's disease by targeting and reducing a protein called amyloid-beta, which is believed to build up in the brains of affected individuals. The idea was that lowering amyloid-beta levels might slow or prevent the progression of memory and cognitive decline. However, clinical trials revealed that semagacestat did not improve symptoms and was associated with adverse effects, leading to the discontinuation of its development. It highlights the complexity of Alzheimer's and the challenges in finding effective treatments focused on amyloid-beta reduction.